GlassScriptPhysician profile
Joann Vu Adams
NPI 1124688189
$4,271.49
in general payments reported to CMS, 2019-2025
16 companies · $2,660 in 2025
The $2,660 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $27.35 · 2021: $230 · 2022: $253 · 2023: $398 · 2024: $573 · 2025: $2,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,613 · Travel and Lodging: $1,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,612.78 |
| Travel and Lodging | $1,017.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,767.30 | 2019-2025 | Rocklatan, Tryptyr, Precision7 |
| Bausch & Lomb Americas INC. | $545.75 | 2022-2025 | Miebo, Zenlens, Xiidra |
| Coopervision INC. | $295.19 | 2019-2024 | Misight Contact Lens, Myday Contact Lens |
| Dompe US, INC. | $267.26 | 2024-2025 | Oxervate |
| Glaukos Corporation | $207.64 | 2021-2025 | Idosetr |
| Amgen INC. | $205.45 | 2024-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $203.94 | 2021-2023 | |
| Johnson & Johnson Vision Care, INC. | $195.35 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $142.74 | 2025 | Xdemvy |
| Apellis Pharmaceuticals, INC. | $125.00 | 2025 | Syfovre |
| Sun Pharmaceutical Industries INC. | $96.56 | 2019 | |
| Rxsight INC | $92.37 | 2024-2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $58.86 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $29.34 | 2025 | Acthar |
| Biotissue Holdings INC. | $23.76 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $14.98 | 2024 | Natacyn, Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joann Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.